Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
ECHO trial
Description:
The ECHO trial was a clinical study comparing contraceptive methods and HIV acquisition among women in sub-Saharan Africa.
Primary topic:
HIV/AIDS drug development and treatment (28%)
Related topics:
HIV/AIDS drug development and treatment (28%),
Reproductive Health and Contraception (24%),
HIV/AIDS Research and Interventions (16%),
Lymphoma Diagnosis and Treatment (12%)
OpenAlex ID:
keywords/echo-trial
Faster title and abstract screening? Evaluating Abstrackr, a semi-automated online screening program for systematic reviewers
2015
·
John Rathbone
, Tammy Hoffmann
, et al.
·
Systematic Reviews
·
213
PDF
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
2012
·
Calvin J. Cohen
, Jean-Michel Molina
, et al.
·
AIDS
·
151
Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials
2014
·
Pablo Tebas
, Michael Sension
, et al.
·
Clinical Infectious Diseases
·
70
Rilpivirine
2012
·
Mark Sanford
·
Drugs
·
53
Effect of gender and race on the week 48 findings in treatment‐naïve, HIV ‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE
2012
·
S Hodder
, K Arasteh
, et al.
·
HIV Medicine
·
49
PDF
Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo)
2013
·
David A Wohl
, Chloe Orkin
, et al.
·
Antiviral Therapy
·
44
Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial
2021
·
Mags Beksinska
, Rodal Issema
, et al.
·
EClinicalMedicine
·
43
PDF
Neurological and psychiatric tolerability of rilpivirine ( TMC 278) vs. efavirenz in treatment‐naïve, HIV ‐1‐infected patients at 48 weeks
2013
·
AM Mills
, A Antinori
, et al.
·
HIV Medicine
·
41
High HIV incidence among young women in South Africa: Data from a large prospective study
2022
·
Thesla Palanee-Phillips
, Helen V. Rees
, et al.
·
PLoS ONE
·
40
PDF
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study
2021
·
Deborah Donnell
, Ivana Beesham
, et al.
·
The Lancet HIV
·
37
Week 96 analysis of rilpivirine or efavirenz in HIV ‐1‐infected patients with baseline viral load ≤ 100 000 copies/m L in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials
2013
·
J‐M Molina
, N Clumeck
, et al.
·
HIV Medicine
·
36
PDF
Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response
2013
·
Johan Vingerhoets
, Laurence Rimsky
, et al.
·
Antiviral Therapy
·
34
PDF
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis
2014
·
Georg Behrens
, Bart Rijnders
, et al.
·
AIDS Patient Care and STDs
·
32
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysis
2013
·
Jean-Michel Molina
, Nathan Clumeck
, et al.
·
AIDS
·
29
Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
2020
·
Janet P. Hapgood
·
AIDS Research and Human Retroviruses
·
28
Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
2023
·
Ivana Beesham
, Cecilia Milford
, et al.
·
BMC Public Health
·
26
PDF
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVE
2010
·
HM Crauwels
, E van Schaick
, et al.
·
Journal of the International AIDS Society
·
26
PDF
Integrating oral PrEP delivery among African women in a large HIV endpoint‐driven clinical trial
2020
·
Ivana Beesham
, Julia D Welch
, et al.
·
Journal of the International AIDS Society
·
25
PDF
Rilpivirine: a step forward in tailored HIV treatment
2011
·
Rik Schrijvers
, Belete Ayele Desimmie
, et al.
·
The Lancet
·
24
Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial
2021
·
Mandisa Singata‐Madliki
, Florence Carayon‐Lefebvre d’Hellencourt
, et al.
·
International Journal of Gynecology & Obstetrics
·
23
PDF
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients
2010
·
C Cohen
, JM Molina
, et al.
·
Journal of the International AIDS Society
·
19
PDF
Contraceptive Continuation and Experiences Obtaining Implant and IUD Removal Among Women Randomized to Use Injectable Contraception, Levonorgestrel Implant, and Copper IUD in South Africa and Zambia
2023
·
Alice F. Cartwright
, Rebecca L. Callahan
, et al.
·
Studies in Family Planning
·
18
Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial
2022
·
Rubina Bunjun
, Tanko F Ramla
, et al.
·
Clinical Infectious Diseases
·
18
Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa
2021
·
Ivana Beesham
, Shannon Bosman
, et al.
·
Contraception
·
18
Genital inflammatory status and the innate immune response to contraceptive initiation
2022
·
Nina Radzey
, Rushil Harryparsad
, et al.
·
American Journal of Reproductive Immunology
·
15
Show more works
View as search
Works count:
113
Citation count:
1,395
Year
Topic
Type